Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.

Speaking at a Bank of America fireside chat, President and CEO Michael Carrel and CFO Angela Wirick discussed the company’s growth targets, profitability trajectory, competitive positioning and clinical trial pipeline. AtriCure delivered 15% revenue growth in 2025 and is guiding for 12% to 14% growth in 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.